Friday, May 13, 2022 8:29:59 AM
$BTAI CG Target $75. Predicts Alzh Dementia irritability success. Sees successful Institutional launch. Increases peak sales estimate ~50% ($934MM from $627MM) TAKEOVER CANDIDATE given approved neurology product scarcity. pic.twitter.com/rh9h7kjT8Q
— The Godfather Knows Best (@mojoblt) May 12, 2022
Recent BTAI News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
